Capsugel’s Dosage Form Solutions (DFS) business unit unveiled extensive upgrades and expansions to three of its manufacturing facilities in the United States and Europe, deepening the company’s finished dosage form capabilities as part of its LIPIDEX technology platform. The multi-million dollar investments broaden the company’s global capabilities to handle hormonal as well as high- potent compounds for soft gelatin and liquid-fill hard capsules (LFHC), responding to a growing demand from its pharmaceutical and health and nutrition customers.
“Investments at our soft gelatin and LFHC facilities reinforce Capsugel’s leadership in liquid-fill technologies and our commitment to offering customers a comprehensive range of services from formulation development to commercial manufacturing. Backed by decades of capsule engineering, specialized formulation know-how and global supply- chain expertise, customers can be assured of high quality encapsulated products using SGcaps and Licaps technology,” said Anthony Macci, SVP of Global Operations. “Our continued expansion and integration of our product development and manufacturing capabilities further ensures that customer projects find optimized solutions, fast.”
Investment highlights include:
Capsugel is a global leader in providing innovative, high-quality dosage forms and solutions for the health care industry. With more than 100 years of experience, we provide a comprehensive array of advanced solutions to pharmaceutical and nutritional customers from formulation through clinical and commercial supply. From hard gelatin, liquid-filled and vegetarian capsules, to product development and manufacturing services, we help our customers improve their product profiles and accelerate development and commercialization timelines. Capsugel is headquartered in Morristown, NJ, employs 2,900 people, has 12 manufacturing and R&D facilities across three continents and serves more than 4,000 customers in over 100 countries. For more information, visit www.capsugel.com.
SOURCE: Capsugel® | Lonza Pharma & Biotech